Inhibikase Therapeutics (IKT) Cash & Equivalents (2019 - 2026)
Inhibikase Therapeutics' Cash & Equivalents was $31.21 million in Q2 2026, down 59.9% from $77.74 million a year earlier and down 37.0% from the prior quarter.
Powered by 
Analysis
Inhibikase Therapeutics (IKT) Cash & Equivalents (2019 - 2026) Analysis & Trends
At the end of FY2025, Cash & Equivalents at Inhibikase Therapeutics came in at $139.22 million, up 146.4% from FY2024.
- Cash & Equivalents has now increased for three consecutive years, with a five-year compound annual growth rate of 58.4% (FY2020 to FY2025).
- In earlier years, Cash & Equivalents was $56.49 million in FY2024 (+516.4%), $9.17 million in FY2023 (+27.5%), $7.19 million in FY2022 (-82.4%) and $40.75 million in FY2021 (+192.0%).
- The Q2 2026 figure marks the lowest quarterly Cash & Equivalents since Q3 2024.
- Compared with a year earlier, Cash & Equivalents was higher in two of the last five quarters, with growth averaging 95.3%.
- The best year-over-year quarter for Cash & Equivalents over five years was Q4 2024 (growth of 516.4%); the worst was Q2 2023 (a decline of 94.1%).
- Per Business Quant data, IKT's Cash & Equivalents in the three quarters before Q2 2026 was $49.57 million (Q1 2026), $139.22 million (Q4 2025) and $38.27 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,348.13 Bn | 1,321.74 Bn | 20.46 Bn | 4.89 Bn |
| 2 | Johnson & Johnson | 675.90 Bn | 595.76 Bn | 17.30 Bn | 16.91 Bn |
| 3 | AbbVie | 519.45 Bn | 487.50 Bn | 13.12 Bn | 10.77 Bn |
| 4 | Merck | 364.95 Bn | 327.95 Bn | 13.19 Bn | 9.55 Bn |
| 5 | Novartis Ag | 311.58 Bn | 285.16 Bn | - | 400.00 Mn |
| 6 | Astrazeneca | 289.34 Bn | 262.94 Bn | 13.26 Bn | 7.94 Bn |
| 7 | Amgen | 251.64 Bn | 203.30 Bn | 7.58 Bn | 13.19 Bn |
| 8 | Gilead Sciences | 212.05 Bn | 187.07 Bn | 6.73 Bn | 6.44 Bn |
| 9 | Pfizer | 167.35 Bn | 115.00 Bn | 12.56 Bn | 1.82 Bn |
| 10 | Inhibikase Therapeutics | 281.11 Mn | -420.36 Mn | - | 51.70 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2026 | 51.70 Mn |
| Jun 30, 2026 | 31.21 Mn |
| Mar 31, 2026 | 49.57 Mn |
| Dec 31, 2025 | 139.22 Mn |
| Sep 30, 2025 | 38.27 Mn |
| Jun 30, 2025 | 77.74 Mn |
| Mar 31, 2025 | 73.44 Mn |
| Dec 31, 2024 | 56.49 Mn |
| Sep 30, 2024 | 913,420.00 |
| Jun 30, 2024 | 3.09 Mn |
| Mar 31, 2024 | 2.35 Mn |
| Dec 31, 2023 | 9.17 Mn |
| Sep 30, 2023 | 14.86 Mn |
| Jun 30, 2023 | 1.91 Mn |
| Mar 31, 2023 | 3.96 Mn |
| Dec 31, 2022 | 7.19 Mn |
| Sep 30, 2022 | 5.78 Mn |
| Jun 30, 2022 | 32.21 Mn |
| Mar 31, 2022 | 36.61 Mn |
| Dec 31, 2021 | 40.75 Mn |
API Access
Inhibikase Therapeutics Cash & Equivalents API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=IKT&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "cash-and-equivalents", "ticker": "IKT", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=cash-and-equivalents&ticker=IKT&period=max&api_key=YOUR_API_KEY");
const data = await res.json();